PRESS RELEASE published on 03/13/2025 at 14:01, 1 year 4 months ago Healthcare Specialist SHS Capital, together with its co-investors, sells Selfapy GmbH to MEDICE - The Health Family SHS Capital and co-investors sell Selfapy GmbH to MEDICE - The Health Family, a step towards clinically validated healthcare solutions integrating pharmaceuticals and digital concepts Healthcare Solutions Digital Health SHS Capital Selfapy GmbH MEDICE
PRESS RELEASE published on 03/13/2025 at 14:00, 1 year 4 months ago Vox Royalty Provides Development Updates and Approval of 2025 Share Repurchase Program Vox Royalty Corp. provides updates on mining royalty partners Black Cat Syndicate Limited, Orla Mining Ltd., and Galway Metals Inc. Recent developments include new acquisitions and progress towards production in Western Australia, Nevada, and Quebec Acquisitions Vox Royalty Corp. Production Mining Royalty Partners
PRESS RELEASE published on 03/13/2025 at 13:45, 1 year 4 months ago bonyf recently secures its EU Patent, US patent pending, for PerioTabs® & PerioCream, launch in March 2025 at the IDS Cologne bonyf secures EU Patent, pending US patent, for PerioTabs® & PerioCream, set to launch at IDS Cologne in March 2025. Products aim to revolutionize dental care practices globally Bonyf PerioTabs EU Patent PerioCream IDS Cologne
PRESS RELEASE published on 03/13/2025 at 13:41, 1 year 4 months ago Form 8.3 - Equals Group PLC Chelverton Asset Management discloses a 1.18% stake in Equals Group PLC. No other disclosures made Stake Chelverton Asset Management Equals Group PLC Disclosures 1.18%
PRESS RELEASE published on 03/13/2025 at 13:38, 1 year 4 months ago REPLY: The Board of Directors approved the draft financial statements for the year 2024 Reply S.p.A. Board of Directors approves draft financial statements for 2024, proposing dividend distribution of €1.15 per share. Positive financial indicators with increased turnover and net profit Board Of Directors Financial Statements Dividend Distribution Reply S.p.A. Positive Indicators
PRESS RELEASE published on 03/13/2025 at 13:30, 1 year 4 months ago Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses Xenetic Biosciences presents promising findings on combining DNase I with CAR T cells to enhance cancer treatment strategies at the SITC Spring Scientific 2025 Cell Therapy Meeting Xenetic Biosciences Cancer Treatment DNase I CAR T Cells SITC Spring Meeting
PRESS RELEASE published on 03/13/2025 at 13:30, 1 year 4 months ago Aspire Biopharma Holdings, Inc., Provides Update on Recently Filed U.S. Patent Applications for Its Sublingual Drug Delivery Platform Aspire Biopharma Holdings, Inc. provides update on patent applications for Oral Mucosal Formulations of Aspirin with rapid absorption technology. Company aims to revolutionize drug delivery and improve patient outcomes Drug Delivery Technology Patent Applications Aspire Biopharma Oral Mucosal Formulations Aspirin
PRESS RELEASE published on 03/13/2025 at 13:18, 1 year 4 months ago Inside Information / Other news releases French Competition Authority approves Carmila's acquisition of Galimmo, Carmila to sell Villers Semeuse shopping gallery in 2025. No significant impact on financial targets Acquisition Competition Authority CARMILA Galimmo Villers Semeuse
PRESS RELEASE published on 03/13/2025 at 13:00, 1 year 4 months ago Prince Holding Group Earns Fifth Consecutive ‘Best in Cambodia’ Award for CSR Initiatives Prince Holding Group recognized as 'Best in Country Excellence - Best in Cambodia' at the 17th Annual Global CSR & ESG Awards for sustainable development efforts. Awards highlight ongoing CSR and ESG initiatives guided by Chairman Chen Zhi Sustainable Development Prince Holding Group Chen Zhi CSR Initiatives Global CSR Awards
PRESS RELEASE published on 03/13/2025 at 13:00, 1 year 4 months ago MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain MIRA Pharmaceuticals introduces topical Ketamir-2 for neuropathic and inflammatory pain, expanding pain management portfolio with innovative targeted approach MIRA Pharmaceuticals Ketamir-2 Neuropathic Pain Topical Treatment Inflammatory Pain
Published on 07/24/2026 at 23:00, 30 minutes ago NV Gold Announces Closing of Non-Brokered Private Placement
Published on 07/24/2026 at 22:15, 1 hour 15 minutes ago Gold Terra Announces Closing of First Tranche of C$10.8M LIFE Offering With Strong Participation From Strategic Shareholder David Harquail
Published on 07/24/2026 at 22:05, 1 hour 25 minutes ago Findev Inc. Announces CCAA Proceedings Involving 1682 Victoria Park Avenue Inc. and Related Party Subordination Arrangement
Published on 07/24/2026 at 20:00, 3 hours 30 minutes ago Unusual Machines to Announce Second Quarter 2026 Financial Results and Provide Corporate Update
Published on 07/24/2026 at 14:00, 9 hours 30 minutes ago NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering
Published on 07/24/2026 at 18:44, 4 hours 46 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 07/24/2026 at 17:50, 5 hours 40 minutes ago Fuller, Smith & Turner PLC: Director / PDMR Shareholding
Published on 07/24/2026 at 17:40, 5 hours 50 minutes ago 2CRSi SA: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital as of May 31, 2026.
Published on 07/24/2026 at 18:50, 4 hours 40 minutes ago Disclosure of transactions in own shares from July 20 to July 24, 2026
Published on 07/24/2026 at 18:11, 5 hours 19 minutes ago H1 2026 liquidity contract statement for TF1
Published on 07/24/2026 at 08:00, 15 hours 30 minutes ago Accor signs a definitive binding agreement on the sale of its stake in Essendi